Table of Content

1 INTRODUCTION (Page No. - 28)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 PRECISION MEDICINE MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
           1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRECISION MEDICINE MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
          FIGURE 5 MARKET SIZE ESTIMATION FOR PRECISION MEDICINE: REVENUE SHARE ANALYSIS
           2.2.1 INSIGHTS FROM PRIMARIES
                    FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.2.2 SEGMENT ASSESSMENT (BY TYPE, INDICATION, AND END USER)
                    FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH FORECAST 
          FIGURE 8 PRECISION MEDICINE INDUSTRY: CAGR PROJECTIONS
          FIGURE 9 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 11 PRECISION MEDICINE MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY INDICATION, 2023 VS. 2028
    FIGURE 13 MARKET, BY END USER, 2023 VS. 2028
    FIGURE 14 GEOGRAPHICAL SNAPSHOT OF MARKET
4 PREMIUM INSIGHTS (Page No. - 47)
    4.1 PRECISION MEDICINE MARKET OVERVIEW 
          FIGURE 15 INCREASING REGULATORY APPROVALS FOR PRECISION MEDICINES TO DRIVE MARKET
    4.2 NORTH AMERICA: MARKET,  BY TYPE AND COUNTRY 
          FIGURE 16 INHIBITOR DRUGS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE  IN NORTH AMERICA (2022)
    4.3 MARKET, BY INDICATION 
          FIGURE 17 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.4 PRECISION MEDICINE INDUSTRY: GEOGRAPHICAL GROWTH OPPORTUNITIES 
          FIGURE 18 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 50)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,  AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing focus on genomic research
                                TABLE 2 INITIATIVES IN GENOMIC RESEARCH AND PRECISION MEDICINE
                    5.2.1.2 Growth in genetic testing and companion diagnostics
                    5.2.1.3 Increasing regulatory approvals for personalized therapeutics
           5.2.2 RESTRAINTS
                    5.2.2.1 High costs of therapeutic development
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising demand for cell and gene therapies
           5.2.4 CHALLENGES
                    5.2.4.1 Challenges associated with adoption of precision medicine
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 3 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 TECHNOLOGY ANALYSIS 
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 20 MARKET: VALUE CHAIN
           5.5.1 RESEARCH & DEVELOPMENT
           5.5.2 MANUFACTURING
           5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES ACTIVITIES
    5.6 ECOSYSTEM ANALYSIS 
          FIGURE 21 MARKET: ECOSYSTEM MAP
    5.7 PATENT ANALYSIS 
          FIGURE 22 PATENT APPLICATIONS FOR PRECISION MEDICINE THERAPEUTIC PRODUCTS (JANUARY 2012–JULY 2023)
          TABLE 4 MARKET: INDICATIVE LIST OF PATENTS
    5.8 PIPELINE ANALYSIS 
          TABLE 5 PRECISION MEDICINE THERAPEUTICS IN CLINICAL PIPELINE
    5.9 SUPPLY CHAIN ANALYSIS 
           5.9.1 PROMINENT COMPANIES
           5.9.2 SMALL AND MEDIUM-SIZED ENTERPRISES
           5.9.3 END USERS
           5.9.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES
           5.9.5 REGULATORY BODIES
                    FIGURE 23 PRECISION MEDICINE THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
                    TABLE 6 MARKET: SUPPLY CHAIN ECOSYSTEM
    5.10 REGULATORY ANALYSIS 
           TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
           TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
           TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
           TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
    5.11 PRICING ANALYSIS 
           5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
                     TABLE 11 AVERAGE SELLING PRICE OF PRECISION MEDICINE THERAPEUTICS
    5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
    5.13 KEY CONFERENCES AND EVENTS 
           TABLE 12 MARKET: DETAILED LIST OF CONFERENCES &  EVENTS (2023–2024)
    5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRECISION MEDICINE THERAPEUTICS IN HOSPITALS AND CLINICS
           5.14.2 BUYING CRITERIA FOR MARKET
                     FIGURE 25 KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS
6 PRECISION MEDICINE MARKET, BY TYPE (Page No. - 72)
    6.1 INTRODUCTION 
          TABLE 13 PRECISION MEDICINE INDUSTRY, BY TYPE, 2021–2028 (USD MILLION)
    6.2 INHIBITOR DRUGS 
           6.2.1 ADVANTAGES OF HIGH ACCURACY AND AFFORDABILITY TO DRIVE MARKET
                    TABLE 14 APPROVED INHIBITOR DRUGS IN MARKET (2022)
                    TABLE 15 MARKET FOR INHIBITOR DRUGS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 16 NORTH AMERICA: MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 17 EUROPE: MARKET FOR INHIBITOR DRUGS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 18 ASIA PACIFIC: MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 MONOCLONAL ANTIBODIES 
           6.3.1 HIGH SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET
                    TABLE 19 MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 20 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 21 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 22 ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 CELL AND GENE THERAPY 
           6.4.1 WIDE APPLICATIONS IN ONCOLOGY THERAPEUTICS TO FUEL MARKET
                    TABLE 23 MARKET FOR CELL AND GENE THERAPY, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 24 NORTH AMERICA: MARKET FOR CELL AND GENE THERAPY,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 25 EUROPE: MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 ASIA PACIFIC: MARKET FOR CELL AND GENE THERAPY,  BY COUNTRY, 2021–2028 (USD MILLION)
    6.5 ANTIVIRAL AND ANTIRETROVIRAL DRUGS 
           6.5.1 MINIMAL SIDE EFFECTS DUE TO TARGETED APPROACH TO SUPPORT MARKET GROWTH
                    TABLE 27 MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 28 NORTH AMERICA: MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 29 EUROPE: MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 30 ASIA PACIFIC: MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
    6.6 OTHER THERAPEUTIC PRODUCTS 
          TABLE 31 MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 32 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 33 EUROPE: MARKET FOR OTHER THERAPEUTIC PRODUCTS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 34 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC PRODUCTS,  BY COUNTRY, 2021–2028 (USD MILLION)
7 PRECISION MEDICINE MARKET, BY INDICATION (Page No. - 84)
    7.1 INTRODUCTION 
          TABLE 35 PRECISION MEMEDICINE INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
    7.2 ONCOLOGY 
           7.2.1 INCREASING PRODUCT APPROVALS FOR CANCER THERAPEUTICS TO DRIVE MARKET
                    TABLE 36 MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 37 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 38 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 39 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
    7.3 RARE DISEASES 
           7.3.1 GROWING FOCUS ON PRODUCT DEVELOPMENT TO DRIVE MARKET
                    TABLE 40 MARKET FOR RARE DISEASES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 41 NORTH AMERICA: MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 42 EUROPE: MARKET FOR RARE DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 43 ASIA PACIFIC: MARKET FOR RARE DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
    7.4 INFECTIOUS DISEASES 
           7.4.1 RISING INCIDENCE OF HIV AND TB TO FUEL MARKET
                    TABLE 44 PRECISION MEDICINE INDUSTRY FOR INFECTIOUS DISEASES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 45 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 46 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 47 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 HEMATOLOGICAL DISORDERS 
           7.5.1 INCREASING CASES OF SICKLE CELL DISEASE AND ANEMIA TO SUPPORT MARKET GROWTH
                    TABLE 48 MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 49 NORTH AMERICA: MARKET FOR HEMATOLOGICAL DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 EUROPE: MARKET FOR HEMATOLOGICAL DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 51 ASIA PACIFIC: MARKET FOR HEMATOLOGICAL DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
    7.6 OTHER INDICATIONS 
          TABLE 52 MARKET FOR OTHER INDICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 53 NORTH AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 54 EUROPE: MARKET FOR OTHER INDICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 55 ASIA PACIFIC: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8 PRECISION MEDICINE MARKET, BY END USER (Page No. - 96)
    8.1 INTRODUCTION 
          TABLE 56 PRECISION MEDICINE INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    8.2 HOSPITALS AND CLINICS 
           8.2.1 WIDE ADOPTION OF PRECISION MEDICINE FOR COMPLEX MEDICAL PROCEDURES TO DRIVE MARKET
                    TABLE 57 MARKET FOR HOSPITALS AND CLINICS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 58 NORTH AMERICA: MARKET FOR HOSPITALS AND CLINICS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 59 EUROPE: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 60 ASIA PACIFIC: MARKET FOR HOSPITALS AND CLINICS,  BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 HOME CARE SETTINGS 
           8.3.1 ADVANTAGES OF PATIENT COMFORT AND REDUCED HOSPITAL STAYS TO SUPPORT MARKET GROWTH
                    TABLE 61 MARKET FOR HOME CARE SETTINGS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 62 NORTH AMERICA: MARKET FOR HOME CARE SETTINGS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 EUROPE: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
9 PRECISION MEDICINE MARKET, BY REGION (Page No. - 102)
    9.1 INTRODUCTION 
          TABLE 65 PRECISION MEDICINE INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 26 NORTH AMERICA: PRECISION MEDICINE MARKET SNAPSHOT
          TABLE 66 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 67 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 68 NORTH AMERICA: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
          TABLE 69 NORTH AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Rising regulatory approvals for therapeutic products to drive market
                                TABLE 70 PERSONALIZED MEDICINE PRODUCT APPROVALS BY US FDA
                                TABLE 71 US: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 72 US: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 73 US: PRECISION MEDICINE INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Rising incidence of cancer to drive market
                                TABLE 74 CANADA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 75 CANADA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 76 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.3 NORTH AMERICA: RECESSION IMPACT
    9.3 EUROPE 
          FIGURE 27 EUROPE: MARKET SNAPSHOT
          TABLE 77 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 78 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 79 EUROPE: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
          TABLE 80 EUROPE: PRECISION MEDICINE INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Rising R&D initiatives for therapeutics to drive market
                                TABLE 81 GERMANY: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 82 GERMANY: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 83 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Rising incidence of hematologic cancers to drive market
                                TABLE 84 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                TABLE 85 UK: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 86 UK: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 87 UK: PRECISION MEDICINE INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Increasing initiatives in genomic research to drive market
                                TABLE 88 FRANCE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 89 FRANCE: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 90 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Growing awareness initiatives for personalized treatment to propel market
                                TABLE 91 ITALY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 92 ITALY: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 93 ITALY: PRECISION MEDICINE INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Rising funding initiatives for cell and gene therapies to support market growth
                                TABLE 94 SPAIN: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 95 SPAIN: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 96 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 97 REST OF EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 98 REST OF EUROPE: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
                    TABLE 99 REST OF EUROPE: PRECISION MEDICINE INDUSTRY, BY END USER,  2021–2028 (USD MILLION)
           9.3.7 EUROPE: RECESSION IMPACT
    9.4 ASIA PACIFIC 
          TABLE 100 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 101 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 102 ASIA PACIFIC: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
          TABLE 103 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 High incidence of chronic diseases and large patient volume to fuel market
                                TABLE 104 CHINA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 105 CHINA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 106 CHINA: PRECISION MEDICINE INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Availability of reimbursements for medical procedures to support market growth
                                TABLE 107 JAPAN: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 108 JAPAN: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 109 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Rising burden of chronic diseases to drive market
                                TABLE 110 INDIA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 111 INDIA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 112 INDIA: PRECISION MEDICINE INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.4.4 AUSTRALIA
                    9.4.4.1 Rising R&D projects for genomic sequencing to propel market
                                TABLE 113 AUSTRALIA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 114 AUSTRALIA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                TABLE 115 AUSTRALIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.5 REST OF ASIA PACIFIC
                    TABLE 116 REST OF ASIA PACIFIC: MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 117 REST OF ASIA PACIFIC: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
                    TABLE 118 REST OF ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.4.6 ASIA PACIFIC: RECESSION IMPACT
    9.5 LATIN AMERICA 
           9.5.1 INVESTMENTS IN PRECISION MEDICINE DIAGNOSTICS TO SUPPORT MARKET GROWTH
                    TABLE 119 LATIN AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 120 LATIN AMERICA: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
                    TABLE 121 LATIN AMERICA: PRECISION MEDICINE INDUSTRY, BY END USER,  2021–2028 (USD MILLION)
           9.5.2 LATIN AMERICA: RECESSION IMPACT
    9.6 MIDDLE EAST 
           9.6.1 RISING AWARENESS OF INNOVATIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH
                    TABLE 122 MIDDLE EAST: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 123 MIDDLE EAST: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
                    TABLE 124 MIDDLE EAST: MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.7 AFRICA 
           9.7.1 INCREASING COLLABORATIVE EFFORTS WITH ESTABLISHED COUNTRIES FOR PRECISION DIAGNOSTICS TO SUPPORT MARKET GROWTH
                    TABLE 125 AFRICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 126 AFRICA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                    TABLE 127 AFRICA: PRECISION MEDICINE INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.8 MIDDLE EAST & AFRICA: RECESSION IMPACT 
10 COMPETITIVE LANDSCAPE (Page No. - 140)
     10.1 OVERVIEW 
             10.1.1 STRATEGIES ADOPTED BY KEY PLAYERS
     10.2 MARKET SHARE ANALYSIS 
             FIGURE 28 PRECISION MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
             TABLE 128 MARKET: INTENSITY OF COMPETITIVE RIVALRY
     10.3 REVENUE SHARE ANALYSIS 
             FIGURE 29 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2020−2022)
     10.4 COMPANY EVALUATION MATRIX 
             FIGURE 30 PRECISION MEDICINE INDUSTRY: COMPANY EVALUATION MATRIX (2022)
             10.4.1 STARS
             10.4.2 PERVASIVE PLAYERS
             10.4.3 EMERGING LEADERS
             10.4.4 PARTICIPANTS
     10.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES 
             FIGURE 31 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
             10.5.1 PROGRESSIVE COMPANIES
             10.5.2 STARTING BLOCKS
             10.5.3 DYNAMIC COMPANIES
             10.5.4 RESPONSIVE COMPANIES
     10.6 COMPETITIVE BENCHMARKING OF LEADING PLAYERS 
             10.6.1 PRODUCT FOOTPRINT OF COMPANIES
                        TABLE 129 PRECISION MEDICINE INDUSTRY: PRODUCT FOOTPRINT ANALYSIS
             10.6.2 REGIONAL FOOTPRINT OF COMPANIES
                        TABLE 130 MARKET: REGIONAL FOOTPRINT ANALYSIS
     10.7 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 
             TABLE 131 PRECISION MEDICINE INDUSTRY: DETAILED LIST OF KEY STARTUPS/SMES
             TABLE 132 PRECISION MEDICINE INDUSTRY: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
     10.8 COMPETITIVE SCENARIO AND TRENDS 
             10.8.1 PRODUCT APPROVALS
                        TABLE 133 MARKET: PRODUCT APPROVALS (JANUARY 2020−JUNE 2023)
             10.8.2 DEALS
                        TABLE 134 MARKET: DEALS (JANUARY 2020−JUNE 2023)
             10.8.3 OTHER DEVELOPMENTS
                        TABLE 135 PRECISION MEDICINE INDUSTRY: OTHER DEVELOPMENTS (JANUARY 2020−JULY 2023)
11 COMPANY PROFILES (Page No. - 154)
(Business overview, Products offered, Recent Developments, MNM view)*
     11.1 KEY PLAYERS 
             11.1.1 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 136 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
                        FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
                        TABLE 137 F. HOFFMANN-LA ROCHE AG: PRODUCT APPROVALS
             11.1.2 BRISTOL MYERS SQUIBB
                        TABLE 138 BRISTOL MYERS SQUIBB: COMPANY OVERVIEW
                        FIGURE 33 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2022)
                        TABLE 139 BRISTOL MYERS SQUIBB: DEALS
                        TABLE 140 BRISTOL MYERS SQUIBB: PRODUCT APPROVALS
             11.1.3 NOVARTIS AG
                        TABLE 141 NOVARTIS AG: COMPANY OVERVIEW
                        FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022)
                        TABLE 142 NOVARTIS AG: DEALS
                        TABLE 143 NOVARTIS AG: PRODUCT APPROVALS
             11.1.4 GILEAD SCIENCES, INC.
                        TABLE 144 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
                        FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 145 GILEAD SCIENCES, INC.: DEALS
                        TABLE 146 GILEAD SCIENCES, INC.: PRODUCT APPROVALS
             11.1.5 ASTRAZENECA
                        TABLE 147 ASTRAZENECA: COMPANY OVERVIEW
                        FIGURE 36 ASTRAZENECA: COMPANY SNAPSHOT (2022)
                        TABLE 148 ASTRAZENECA: DEALS
                        TABLE 149 ASTRAZENECA: PRODUCT APPROVALS
             11.1.6 ABBVIE INC.
                        TABLE 150 ABBVIE INC.: COMPANY OVERVIEW
                        FIGURE 37 ABBVIE INC.: COMPANY SNAPSHOT (2022)
                        TABLE 151 ABBVIE INC.: DEALS
             11.1.7 ELI LILLY AND COMPANY
                        TABLE 152 ELI LILLY AND COMPANY: COMPANY OVERVIEW
                        FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
                        TABLE 153 ELI LILLY AND COMPANY: DEALS
                        TABLE 154 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
             11.1.8 SAREPTA THERAPEUTICS, INC.
                        TABLE 155 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
                        FIGURE 39 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)
                        TABLE 156 SAREPTA THERAPEUTICS, INC.: DEALS
                        TABLE 157 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS
                        TABLE 158 SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS
             11.1.9 PFIZER INC.
                        TABLE 159 PFIZER INC.: COMPANY OVERVIEW
                        FIGURE 40 PFIZER INC.: COMPANY SNAPSHOT (2022)
                        TABLE 160 PFIZER INC.: DEALS
                        TABLE 161 PFIZER INC.: PRODUCT APPROVALS
                        TABLE 162 PFIZER INC.: OTHER DEVELOPMENTS
             11.1.10 GLAXOSMITHKLINE PLC
                        TABLE 163 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
                        FIGURE 41 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)
                        TABLE 164 GLAXOSMITHKLINE PLC: DEALS
                        TABLE 165 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS
             11.1.11 SANOFI
                        TABLE 166 SANOFI: COMPANY OVERVIEW
                        FIGURE 42 SANOFI: COMPANY SNAPSHOT (2022)
                        TABLE 167 SANOFI: DEALS
                        TABLE 168 SANOFI: PRODUCT APPROVALS
             11.1.12 JOHNSON & JOHNSON
                        TABLE 169 JOHNSON & JOHNSON: COMPANY OVERVIEW
                        FIGURE 43 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
                        TABLE 170 JOHNSON & JOHNSON: PRODUCT APPROVALS
             11.1.13 BLUEBIRD BIO, INC.
                        TABLE 171 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
                        FIGURE 44 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 172 BLUEBIRD BIO, INC.: PRODUCT LAUNCHES
                        TABLE 173 BLUEBIRD BIO, INC.: PRODUCT APPROVALS
             11.1.14 MERCK KGAA
                        TABLE 174 MERCK KGAA: COMPANY OVERVIEW
                        FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022)
                        TABLE 175 MERCK KGAA: PRODUCT APPROVALS
             11.1.15 AMGEN, INC.
                        TABLE 176 AMGEN, INC.: COMPANY OVERVIEW
                        FIGURE 46 AMGEN, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 177 AMGEN, INC.: DEALS
                        TABLE 178 AMGEN, INC.: PRODUCT APPROVALS
             11.1.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED
                        TABLE 179 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
                        FIGURE 47 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
                        TABLE 180 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
             11.1.17 REGENERON PHARMACEUTICALS, INC.
                        TABLE 181 REGENERON PHARMACEUTICALS, INC.: COMPANY OVERVIEW
                        FIGURE 48 REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 182 REGENERON PHARMACEUTICALS, INC.: DEALS
                        TABLE 183 REGENERON PHARMACEUTICALS, INC.: PRODUCT APPROVALS
             11.1.18 IMMUNOCORE LTD.
                        TABLE 184 IMMUNOCORE LTD.: COMPANY OVERVIEW
                        FIGURE 49 IMMUNOCORE LTD.: COMPANY SNAPSHOT (2022)
                        TABLE 185 IMMUNOCORE LTD.: DEALS
                        TABLE 186 IMMUNOCORE LTD.: PRODUCT APPROVALS
             11.1.19 BLUEPRINT MEDICINES CORPORATION
                        TABLE 187 BLUEPRINT MEDICINES CORPORATION: COMPANY OVERVIEW
                        FIGURE 50 BLUEPRINT MEDICINE: COMPANY SNAPSHOT (2022)
                        TABLE 188 BLUEPRINT MEDICINES CORPORATION: DEALS
                        TABLE 189 BLUEPRINT MEDICINES CORPORATION: PRODUCT APPROVALS
     11.2 OTHER PLAYERS 
             11.2.1 VERTEX PHARMACEUTICALS INCORPORATED
             11.2.2 MIRATI THERAPEUTICS, INC
             11.2.3 ARGENX SE
             11.2.4 HORIZON THERAPEUTICS PLC
             11.2.5 BRIDGEBIO PHARMA, INC.
             11.2.6 TREVENA, INC.
             11.2.7 INCYTE CORPORATION
             11.2.8 ALNYLAM PHARMACEUTICALS, INC.
             11.2.9 RIGEL PHARMACEUTICALS, INC.
             11.2.10 TAIHO PHARMACEUTICAL CO., LTD  (PART OF OTSUKA HOLDINGS CO., LTD.)
             11.2.11 AGIOS PHARMACEUTICALS, INC.
             11.2.12 SEAGEN, INC.
             11.2.13 RHYTHM PHARMACEUTICALS, INC.
             11.2.14 MACROGENICS, INC.
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 233)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS